HCW Biologics Company Insiders

HCW Biologics Management Team Effectiveness

The company has return on total asset (ROA) of (0.4707) % which means that it has lost $0.4707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3246) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 12, 2024, Return On Tangible Assets is expected to decline to -0.92. In addition to that, Return On Capital Employed is expected to decline to -1.37. At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Current Assets Total are forecasted to decline to about 11.7 M. As of June 12, 2024, Common Stock Shares Outstanding is expected to decline to about 28.9 M. In addition to that, Net Loss is expected to decline to about (14.1 M)

HCW Biologics Workforce Comparison

HCW Biologics Insider Trading

HCW Biologics Notable Stakeholders

The success or failure of an entity such as HCW Biologics often depends on how effective the management is. HCW Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HCW management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HCW management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in HCW Biologics' official financial statements typically reflect HCW Biologics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving HCW Biologics' quantitative information. For example, before you start analyzing numbers published by HCW accountants, it’s essential to understand HCW Biologics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.

When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.